Levebon (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. By stabilizing neuronal firing, it lowers neuronal excitability and prevents the spread of abnormal electrical activity that leads to seizures.

The appropriate dose of Levebon is determined by the prescribing clinician based on the patient’s age, weight, renal function and seizure type. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety data for levetiracetam in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against possible risks and discuss alternative options when appropriate. Women who are pregnant or nursing should consult their physician before using Levebon.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levebon (levetiracetam) offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It is generally well‑tolerated, has fewer drug‑enzyme interactions, and is often chosen when patients experience side effects with other agents.

Levebon should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Levebon is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not chewed or crushed unless specifically instructed.

Serious risks include severe allergic reactions, mood alterations such as depression or suicidal thoughts, and rare blood disorders. Patients should seek immediate medical attention if they experience rash, swelling, difficulty breathing, profound mood changes, or signs of infection.

Levebon is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric conditions, or those taking interacting medications without close monitoring.